Advanced

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

Riihijarvi, Sari; Nurmi, Heidi; Holte, Harald; Bjorkholm, Magnus; Fluge, Oystein; Pedersen, Lars Moller; Fjordén, Karin LU ; Jerkeman, Mats LU ; Eriksson, Mikael LU and Leppa, Sirpa (2012) In European Journal of Haematology 89(5). p.395-402
Abstract
Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients <65yrs with high-risk DLBCL using a quantitative sandwich enzyme immunoassay technique. Exon array data set of tumor tissues from 32 patients was concurrently used to determine VEGF-A exon and gene expression. All patients were treated in a Nordic phase II study with six dose-dense chemoimmunotherapy courses followed by systemic central nervous system prophylaxis. Results After a median follow-up time of 40months, 3-yr progression-free... (More)
Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients <65yrs with high-risk DLBCL using a quantitative sandwich enzyme immunoassay technique. Exon array data set of tumor tissues from 32 patients was concurrently used to determine VEGF-A exon and gene expression. All patients were treated in a Nordic phase II study with six dose-dense chemoimmunotherapy courses followed by systemic central nervous system prophylaxis. Results After a median follow-up time of 40months, 3-yr progression-free survival (PFS) was inferior in patients with high s-VEGF levels compared to those with low levels (59% vs. 83%, P=0.005). The relative risk of progression or relapse was 3.1-fold (95% confidence interval 1.346.91, P=0.008). The predictive capacity of s-VEGF levels on PFS was most pronounced in the DLBCLs of non-germinal center subtype. In contrast to serum data, VEGF mRNA expression in the lymphoma tissue did not predict outcome, and no correlation was found between s-VEGF levels and lymphoma VEGF expression. Conclusion Pretreatment s-VEGF level is a predictor of PFS after chemoimmunotherapy and may help to further stratify high-risk DLBCL patients into low- and high-risk groups. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
diffuse large B-cell lymphoma, prognostic factors, vascular endothelial, growth factor, serum, ELISA, gene expression, exon array
in
European Journal of Haematology
volume
89
issue
5
pages
395 - 402
publisher
Wiley-Blackwell
external identifiers
  • wos:000309917500003
  • scopus:84867467631
ISSN
1600-0609
DOI
10.1111/ejh.12005
language
English
LU publication?
yes
id
44789e23-0e3d-48e4-ad90-2b626db910fc (old id 3284153)
date added to LUP
2013-01-07 09:42:29
date last changed
2017-08-06 03:13:49
@article{44789e23-0e3d-48e4-ad90-2b626db910fc,
  abstract     = {Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients &lt;65yrs with high-risk DLBCL using a quantitative sandwich enzyme immunoassay technique. Exon array data set of tumor tissues from 32 patients was concurrently used to determine VEGF-A exon and gene expression. All patients were treated in a Nordic phase II study with six dose-dense chemoimmunotherapy courses followed by systemic central nervous system prophylaxis. Results After a median follow-up time of 40months, 3-yr progression-free survival (PFS) was inferior in patients with high s-VEGF levels compared to those with low levels (59% vs. 83%, P=0.005). The relative risk of progression or relapse was 3.1-fold (95% confidence interval 1.346.91, P=0.008). The predictive capacity of s-VEGF levels on PFS was most pronounced in the DLBCLs of non-germinal center subtype. In contrast to serum data, VEGF mRNA expression in the lymphoma tissue did not predict outcome, and no correlation was found between s-VEGF levels and lymphoma VEGF expression. Conclusion Pretreatment s-VEGF level is a predictor of PFS after chemoimmunotherapy and may help to further stratify high-risk DLBCL patients into low- and high-risk groups.},
  author       = {Riihijarvi, Sari and Nurmi, Heidi and Holte, Harald and Bjorkholm, Magnus and Fluge, Oystein and Pedersen, Lars Moller and Fjordén, Karin and Jerkeman, Mats and Eriksson, Mikael and Leppa, Sirpa},
  issn         = {1600-0609},
  keyword      = {diffuse large B-cell lymphoma,prognostic factors,vascular endothelial,growth factor,serum,ELISA,gene expression,exon array},
  language     = {eng},
  number       = {5},
  pages        = {395--402},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Haematology},
  title        = {High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy},
  url          = {http://dx.doi.org/10.1111/ejh.12005},
  volume       = {89},
  year         = {2012},
}